Replies to post #164602 on Biotech Values

[DewDiligence]

MNTA—Thanks for posting the Bloomberg piece on Teva’s thrice-weekly Copaxone. I previously predicted that this product will garner at most 15-20% of the US Copaxone market (#msg-87522151), so the UBS analyst (Marc Goodman) and I are on the same wavelength. Regards, Dew